Literature DB >> 22200079

Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.

Karthick Raja Muthu Raja, Lucie Kovarova, Roman Hajek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22200079     DOI： 10.3109/10428194.2011.652106

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

1.  The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.

Authors:  Myriam Foglietta; Barbara Castella; Sara Mariani; Marta Coscia; Laura Godio; Riccardo Ferracini; Marina Ruggeri; Vittorio Muccio; Paola Omedé; Antonio Palumbo; Mario Boccadoro; Massimo Massaia
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

2.  Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation.

Authors:  Monika Anna Grygorowicz; Ilona Sara Borycka; Eliza Nowak; Ewa Paszkiewicz-Kozik; Grzegorz Rymkiewicz; Katarzyna Błachnio; Marzena Biernacka; Mateusz Bujko; Jan Walewski; Sergiusz Markowicz
Journal:  Clin Exp Med       Date:  2016-03-10       Impact factor: 3.984

3.  Absolute Lymphocyte Counts After Lenalidomide Initiation may Predict the Prognosis of Patients With Relapsed or Refractory Multiple Myeloma.

Authors:  Masaru Nakagawa; Noriyoshi Iriyama; Takuto Ishikawa; Katsuhiro Miura; Yoshihito Uchino; Hiromichi Takahashi; Takashi Hamada; Kazuhide Iizuka; Takashi Koike; Kazuya Kurihara; Tomohiro Nakayama; Yoshihiro Hatta; Masami Takei
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 4.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

Review 5.  Context-Dependent Effect of Glucocorticoids on the Proliferation, Differentiation, and Apoptosis of Regulatory T Cells: A Review of the Empirical Evidence and Clinical Applications.

Authors:  Luigi Cari; Francesca De Rosa; Giuseppe Nocentini; Carlo Riccardi
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

Review 6.  Regulatory T cells in allogeneic stem cell transplantation.

Authors:  Maria Michael; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2013-05-08

7.  Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients.

Authors:  Karthick Raja Muthu Raja; Roman Hajek
Journal:  Oncoimmunology       Date:  2013-07-09       Impact factor: 8.110

Review 8.  Immunological dysregulation in multiple myeloma microenvironment.

Authors:  Alessandra Romano; Concetta Conticello; Maide Cavalli; Calogero Vetro; Alessia La Fauci; Nunziatina Laura Parrinello; Francesco Di Raimondo
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

9.  Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role.

Authors:  Giovanni D'Arena; Giovanni Rossi; Luca Laurenti; Teodora Statuto; Fiorella D'Auria; Luciana Valvano; Vittorio Simeon; Aldo Giudice; Idanna Innocenti; Vincenzo De Feo; Rosanna Filosa; Pellegrino Musto
Journal:  J Immunol Res       Date:  2016-07-14       Impact factor: 4.818

10.  Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Authors:  Laurens E Franssen; Inger S Nijhof; Chad C Bjorklund; Hsiling Chiu; Ruud Doorn; Jeroen van Velzen; Maarten Emmelot; Berris van Kessel; Mark-David Levin; Gerard M J Bos; Annemiek Broijl; Saskia K Klein; Harry R Koene; Andries C Bloem; Aart Beeker; Laura M Faber; Ellen van der Spek; Reinier Raymakers; Pieter Sonneveld; Sonja Zweegman; Henk M Lokhorst; Anjan Thakurta; Xiaozhong Qian; Tuna Mutis; Niels W C J van de Donk
Journal:  Oncotarget       Date:  2018-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.